Kiebhi kia tena ku saka o uhaxi ua kijimbu mu manhinga?
O ji dotolo a tena ku saka o uhaxi ua izavu mu maukexilu avulu, kala o uhaxi u sambukila, o uhaxi u sambukila, ni ukexilu ua muthu.
O maukexilu a mukuá a ku saka, alungu ni:
1. Ku langa kiambote o uhaxi: O ukexilu iú ua ku saka, u kuatekesa o muthu ku mona se uala ni uhaxi mu veji dia ku mateka ku mu saka ni lusolo.
O milongo íii a tokala ku i bhana ku mala ala ni uhaxi ua bhonzo ua izavu.
2. Ku bhanga pelasá: O pelasá íii, o ku katula o kijimbu kia kijimbu.
O ji dotolo a tena ku bhanga kiki, mu ku bhanga pelasá mba ku bhanga pelasá mu kididi kia ku saka.
3. Milongo phala ku saka o uhaxi ua izavu: O milongo íii, i jibha o ji célula ja uhaxi.
O milongo íii a tena ku i ta bhu kanga dia mukutu ua muthu, mba ku i ta ku mukutu ua muthu, mu kididi bhua zukama o kijimbu.
4. Milongo phala ku sosolola o jihanji ja diiala: O milongo íii, i sosolola o jihanji ja diiala ja ku kala ni ahatu, phala ku sosolola o jihanji ja diiala ja ku kala ni ahatu.
O milongo íii a tena ku i bhana ni lusolo mba ku i ta mu milongo ia mukuá.
5. O milongo íii, i kuatekesa ku jibha o ji célula ja câncer.
O milongo íii a tena ku i bhana se o uhaxi ua bhonzo ua di muange mu idiandu ia mukuá ia mukutu.
6. Milongo phala ku fidisa o uhaxi: O milongo íii, i kuatekesa o mukutu ku di bhana ni uhaxi.
O milongo íii a i bhange phala ku kuatekesa o muthu ua kate.
7. Milongo phala ku kuatekesa o ji célula ja câncer ku kula kiambote.
O milongo íii a i bhange phala ku kuatekesa o muthu ua kate.
8. O milongo íii, i kuatekesa o ji célula ja uhaxi ua izavu ku kala ni mbambi iavulu.
O milongo íii a tena ku i bhana se o uhaxi ua bhonzo, mba ua mu vutuka.
9. O ji makina ji kuatekesa o uongo ua muthu ku kala ni nguzu iavulu (ultrassom): O ji makina jiji ji kuatekesa o uongo ua muthu ku kala ni nguzu iavulu phala ku jibha o ji célula ja uhaxi.
O milongo íii a tena ku i bhana se o uhaxi ua bhonzo, mba ua mu vutuka.
10. Ku langa o uhaxi: O ukexilu iú ulombolola ku langa o uhaxi, ni ku bhanga pelasá izuua ioso, maji o muthu ka tokala ku tambula milongo, se o uhaxi ki ua mu dimendala dingi.
O milongo íii a tokala ku i bhana ku maiala a kuka kiá, ala ni uhaxi ua bhonzo ua ku seluka o ji célula, ni mauhaxi a mukuá.
Kima kiambote kuzuela ni dotolo ia lungu ni ukexilu ua kusaka u ua tokala ku kaiela.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
['Kitendelesu:']
['O kijimbuete kiki, phala ku longa ngó, ki kiene mu bhana milongi ia lungu ni sauidi.']
['O milongi íii, ka tokala ku i tumbula phala ku saka uhaxi, mba ku saka mauhaxi a mukuá.']
['Mu kifika, o ji komputadolo jene mu kuatekesa o athu kuijiia o ima ia lungu ni uhaxi, ki ji tena ku jimbulula kiambote o maka.']
['Sota kikuatekesu kia dotolo iê mba muthu ua mukuá uala ni uhete ua ku saka mauhaxi. Kana ku jimba o itendelesu ia dotolo mukonda dia milongi i ua tange mu kijimbuete kiki. Se ua mesena kikuatekesu, xinda ku muxinda ua 112, mba ndé mu inzo ia ku saka ia zukama.']
['Iala ni Kikutu ni Jinguvulu ja Jixi Jengi']
['O Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (o DMCA) i bhana ku athu ala ni ufolo ua ku soneka, o ima ia mona mu Internete, i bhukumukina o ufolo uâ ua ku soneka. ']
['Se eie u xikina ni kidi kioso kuila o milongi mba milongi i ua mu tanga mu kijimbuete kietu kia internete, mba mu ima ia mukuá, ia mu bhukumukina o itumu iê, eie (mba o muthu u ua mu tumina) u tena ku tu tumikisa mukanda ni ku tu bhinga phala ku katula o milongi mba milongi i ua mu tanga mba ku fidisa o muthu ku i tanga.']
['O ngolokela a tokala ku i tumikisa mu mukanda ni mu kijimbuete kia i-me-le (Tala o mbandu "Utuameni ua Ijimbuete") ].']
['O DMCA i bhinga kuila o njimbu iê ia lungu ni ku bhukumukina o itumu ia ku tokala, i kala ni milongi íii: (1) kijimbuluilu kia kikalakalu kia tokala ku kitumu kia ku tokala; (2) kijimbuluilu kia milongi ia ku tokala ni milongi i tua tokala ku sanga; (3) o ijimbuete iê, ni ijimbuete ia mutelembe uê; (4) ni izuelu i ua zuela kuila eie u xikina ni kidi kioso kuila o milongi ia ku tokala, ki i tokala ku ngana ia tokala, mba ku mukunji uê, mba ku kitumu kioso-kioso; ']
['(5) O kijimbuete kiê, ni kijimbuete kia ku tangela kuila o milongi iala mu kijimbuete kiki ia kidi, ni kuila eie uala ni kutena kua ku langa o ima ia ku tokala;']
['O kijimbuete kiki, ki tena ku kala ni kidimbu kiê, mba kijimbuete kia muthu ua mu tumina o ku ki jikula.']
['Se ku soneka o ima ioso íii, o ku tokuesa o maka mê kua-nda laleka.']
['Kuzuela ni Muthu']
['Tua ku dióndo, tu tumikise njimbu ni ibhuidisu mba jindunge.']
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['O ku']
['O BioMedLib i kalakala ni ji komputadolo phala ku bhanga ibhuidisu ni itambuijilu.']
['Tua mateka ni 35 a mazunda a madivulu a lungu ni sauidi mu internete, ni madivulu a mukuá a ubhe.']
['Tanga o mbandu "Referências" ni mbandu "Disclaimer".']
